---
title: "VK2735 in Chronic weight management: Dosage forms and strengths"
description: "Formulary evidence on VK2735 in Chronic weight management: Dosage forms and strengths. Topics: Subcutaneous formulation: vial and syringe, then autoinjector, in phase 3; Subcutaneous formulation: phase 3 dose strengths; Oral formulation: once-daily tablet and phase 3 dose strengths; Subcutaneous and oral formulations: contracted finished-product formats. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Subcutaneous formulation: vial and syringe, then autoinjector, in phase 3

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735. In the fourth quarter of 2025, we initiated a bioequivalence study to allow for the introduction of an autoinjector device, which may represent a more convenient method of administration for some people.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector. I think for VANQUISH 2, almost everybody is on the auto-injector.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-2.1.2.2-2"></a>

### Subcutaneous formulation: phase 3 dose strengths

> “Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.2-3"></a>

### Oral formulation: once-daily tablet and phase 3 dose strengths

> “In addition to its subcutaneous formulation, Viking is also advancing an oral tablet formulation of VK2735.”
> “Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.2-4"></a>

### Subcutaneous and oral formulations: contracted finished-product formats

> “Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply”
> “This includes dedicated manufacturing lines and an annual commitment to supply 100 million autoinjectors and an additional 100 million vial and syringe products for the subcutaneous formulation, as well as an annual capacity of over one billion oral VK2735 tablets.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

<a id="topic-2.1.2.2-5"></a>

### Commercial strengths, package configuration, and national drug code

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
